GenSight Biologics closes its approximately €2 million fundraising with Invus and Heights Capital
The transaction, announced on November 20, 2026, was subscribed by two existing shareholders, Invus and Heights Capital, and completes the fundraising carried out in October 2026.
The biotech company, which develops gene therapies for neurodegenerative diseases of the retina, is still awaiting structural funding for its RECOVER phase 3 trial.
A runway aligned with the first payments of the RECOVER trial
The net proceeds of the transaction amount to approximately €1.05 million. They will be used to finance operating activities and working capital requirements, in addition to revenues from early access programs.
The financing runway corresponds to the timing of the first significant payments related to the preparation of the RECOVER trial. It remains contingent on the number of patients treated under the French named-patient early access program (AAC) being in line with the company's estimates.
The cash flow projections do not include any exercise of the warrants issued in connection with this transaction. If all of them were exercised, GenSight Biologics would receive approximately €0.93 million in additional gross proceeds.
Chief Financial Officer Jan Eryk Umiastowski stated: “With this financing, we have completed, on schedule, the fundraising of approximately €2 million that we announced with our half-year results.” According to him, the renewed commitment of the two investors allows the company to “approach our upcoming discussions with regulatory authorities with confidence.”
7% discount, 60-month warrants and dilution of non-participating shareholders
The transaction took the form of a capital increase with waiver of preferential subscription rights, with no priority period, under a structure similar to the financings of March and October 2026. It covers 4,237,288 new shares, 13,157,898 pre-funded warrants and 17,395,186 share subscription warrants.
The issue price of €0.0708 per share with one warrant represents a nominal discount of 7% to the closing price on November 19, 2026, of €0.0761. The exercise price of the warrants, i.e. €0.0913 per share, represents a 20% premium to this price, and the warrants are exercisable for 60 months.
The share capital will comprise 250,454,618 shares after the issue, and up to 272,310,109 in the event all warrants are exercised. A shareholder holding 1% of the capital and not having participated would see its stake fall to 0.98%, then to 0.90% after exercise of all warrants, on a non-diluted basis.
On a diluted basis, Invus will hold 24.4% of the capital, compared with 21.5% before the transaction, and Heights Capital 18.3%, compared with 17.9%. The 4,237,288 ordinary shares issued in connection with the transaction are expected to be admitted to trading on Euronext Paris on November 24, 2026, without lock-up commitment. Shares resulting from the exercise of the warrants will be admitted later, as they are issued.